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Purpose. To report the visual acuity (VA) outcomes and culture results of delayed-onset bleb-associated endophthalmitis (BAE)
with and without intravitreal dexamethasone (IVD). Methods. Retrospective nonrandomized comparative case series of BAE at
Bascom Palmer Eye Institute between January 1, 1996 and December 31, 2009. Clinical data were compared using the 2-sided
Student’s t-test for patients who received IVD and patients who did not receive IVD. Results. 70/83 (84%) received IVD, and
13/83 (16%) did not receive IVD. Mean baseline VA was 20/90 in the IVD group and 20/70 in the group that did not receive IVD
(P = 0.57). Mean presenting VA was 0.9/200 in the IVD group and 1.7/200 in the group that did not receive IVD (P = 0.23).
Repeat cultures were positive in 2/70 (3%) IVD cases and 1/13 (8%) cases that did not receive IVD (P = 0.57). Mean VA at 1
month was 5/200 in the IVD group and 1.8/200 in the group that did not receive IVD, logMARΔ of 0.85 and 1.56, respectively
(P = 0.02). Mean VA at 3 months was 7/200 in the IVD group and 3/200 in the group that did not receive IVD, logMARΔ of
0.74 and 1.33, respectively (P = 0.14). Conclusion. In the current study of BAE, IVD was associated with improved short-term VA
outcomes without an increased rate of persistent infection.
1.Introduction
Since 1974 intravitreal dexamethasone (IVD) has been used
as an adjunct to intravitreal antibiotics in the management
of bacterial endophthalmitis [1–3]. In 1992, Irvine et al.
reported favorable outcomes in a series of Gram-negative
endophthalmitis cases treated with adjunctive IVD [2]. In
2004 43% of retina specialists responded that they use IVD
in the management of postcataract endophthalmitis [4]. The
role of IVD in the management of bacterial endophthalmitis
remains controversial due to contradictory results reported
by small, comparative studies [5–8].
Indelayed-onsetbleb-associatedendophthalmitis(BAE),
the majority of reported cases, 53–82%, received adjunctive
IVD [9–12]. No BAE series however has yet reported the
VA outcomes of cases treated with and without IVD. Unlike
postcataract endophthalmitis, BAE is commonly associated
with virulent Streptococcus and Gram-negative organisms
[10–13]. If IVD potentiates intraocular infection then VA
outcomes may be worse in BAE cases treated with IVD.
Additionally, theculturedata ofsecondbiopsies in BAEcases
treated with IVD may manifest a higher rate of persistent
infection. The current study reports the VA outcomes and
culture results of BAE cases treated with and without IVD
to further clarify the role IVD plays in the management of
bacterial endophthalmitis.
2. Methods
The study protocol was approved by the Institutional Review
Board of the University of Miami Miller School of Medicine
Subcommittee for the Protection of Human Subjects in
Research. The medical records and microbiologic records of
all patients treated for BAE at Bascom Palmer Eye Institute
(BPEI)betweenJanuary1,1996andDecember31,2009were
reviewed. As a nonrandomized comparative case series the
decision to use or not use IVD was made by the individual2 International Journal of Inﬂammation
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Figure 1: Photographs of the left eye of 55-year-old male presenting with BAE from Moraxella. (a) Presenting VA: HM, IOP: 19mmHg.
Treatment: pars plana vitrectomy with intravitreal Vancomycin, Ceftazidime, and Dexamethasone. (b) At 3 months VA: 20/40, IOP:
14mmHg.
treatingphysiciananddidnotinvolveaprospectiveprotocol.
All patients had prior glaucoma ﬁltering surgery. BAE was
deﬁned as intraocular infection with vitreous involvement
receiving treatment with intravitreal antibiotics. Patients
with tube shunts as the ﬁltering mechanism, bleb infection
only (no posterior inﬂammation), onset within 1 month of
glaucoma surgery, and inadvertent ﬁltering blebs after
cataract surgery were excluded. Clinical history and presen-
tation, treatment, intraocular culture data, VA outcomes,
and factors aﬀecting VA were recorded. The current study
included clinical information from the BPEI series of BAE
previously published [9, 13].
Snellen VAs were converted to logMAR equivalents for
statistical analysis; VAs of HM, LP, and NLP were assigned
logMAR values of 2.6, 3, and 4 respectively. Change in VA
was determined by comparing the last recorded VA before
the onset of endophthalmitis (pre-endophthalmitis VA) with
VA at 1 and 3 months. Three or more lines of improvement
(≥3 lines improvement) were determined by comparing the
VA at presentation of endophthalmitis (presentation VA)
with the VA at 1 and 3 months. The mean logMAR change
after presentation (logMARΔ) and other clinical data were
grouped according to IVD use and compared using the
2-sided Student’s t-test. Logistic regression was used to
determine the odds ratio for IVD as a predictive factor for
≥3 lines improvement. A P value of ≤0.05 was considered
statistically signiﬁcant.
3. Results
In the current study, 86 eyes were identiﬁed. Excluded were
1 eye with a preexisting tube shunt and 2 eyes that under-
went primary evisceration. Of the 83 eyes, 70 (84%) received
IVD and 13 (16%) did not receive IVD. None of the pa-
tients received systemic steroid. In all cases, the causative
organisms were sensitive to the intravitreal antibiotics clini-
cally administered. Baseline demographics, clinical presen-
tation, and initial culture results were similar between the
two groups with a few exceptions (Table 1).
A greater percentage of IVD cases presented with poor
view of the fundus, 69% compared to 39%. The majority of
both groups received an initial treatment of tap and injection
(T&I); however, a higher percentage received pars plana
vitrectomy (PPV) in the IVD group, 41% compared to 8%.
Also a higher percentage of IVD cases were culture-positive,
66% compared to 46%, but this diﬀerence did not reach
signiﬁcance.
Repeat cultures were performed during a second pro-
cedure in 11/70 (16%) IVD cases and 3/13 (23%) of cases
that did not receive IVD (Table 2).There was no signiﬁcant
diﬀerence in primary or repeat culture-positive results
between the two groups. The repeat culture-positive rate was
2/70 (3%) for IVD cases and 1/13 (8%) for the cases that
did not receive IVD. In each of these 3 cases the same caus-
ative organism was isolated in the repeat culture as in the
initial culture. Repeat cultures were positive in 1/21 (5%)
Streptococcus and 2/6 (33%) Enterococcus cases.
IVD cases had worse mean pre-endophthalmitis and
presentation VA but this did not reach signiﬁcance (Table 3).
At1monthmeanVAwas5/200intheIVDgroupand1.8/
200 in the group that did not receive IVD, logMARΔ of 0.85
and 1.56, respectively (P = 0.02). At 3 months mean VA
was 7/200 in the IVD group and 3/200 in the group that
did not receive IVD, logMARΔ of 0.74 and 1.33, respectively
(P = 0.14). A higher percentage of IVD cases achieved ≥3
lines improvement at 1 and 3 months. Logistic regression
showed that IVD was a signiﬁcant predictive factor of ≥3
lines improvement at both 1 and 3 months (Table 4).
4. Discussion
Corticosteroids are often used as an important adjunct to
antibiotics and PPV in the management of infectious bac-
terial endophthalmitis (Figure 1). Corticosteroids are known
to reduce the degree of inﬂammation caused by toxins
liberated from microorganisms. The role of IVD in the
management of postcataract bacterial endophthalmitis is
unclear due to contradictory results of small, comparative
studies (Table 5).International Journal of Inﬂammation 3
Table 1: Baseline demographics, clinical presentation, and initial
culture results.
IVD No IVD P value
70/83 (84%) 13/83 (16%)
Age
Mean, SD 74yr (12) 70yr (14) 0.27
Gender
Female 34 (49%) 8 (62%) 0.39
Male 36 (51%) 5 (39%)
Diabetes mellitus
Present 9 (13%) 2 (15%) 0.81
Absent 61 (87%) 11 (85%)
Antimetabolites
(MMC or 5FU)
Used 45 (64%) 7 (54%) 0.47
Not used 25 (36%) 6 (46%)
Mean time of onset, SD 60mo (43) 49mo (55) 0.46
Bleb leak
Present 16 (23%) 5 (38%) 0.23
Absent 54 (77%) 8 (62%)
Anterior chamber
Hypopyon 48 (69%) 10 (77%) 0.55
View to fundus
Hazy 22 (31%) 8 (62%) 0.04
Poor/none 48 (69%) 5 (39%)
Intraocular Pressure
Presentation, SD 20 (14) 19 (12) 0.8
Treatment, initial
Tap and injection 41 (59%) 12 (92%) 0.03
Pars plana vitrectomy 29 (41%) 1 (8%)
Treatment, additional
Filtering procedure 12 (17%) 1 (8%) 0.39
Pars plana vitrectomy 21 (30%) 2 (15%) 0.28
Culture results
Culture positive 46 (66%) 6 (46%) 0.18
Culture negative 24 (34%) 7 (54%)
Gram-positive cases 33 (47%) 4 (31%) 0.28
Streptococcus 19 (27%) 2 (15%) 0.37
Coagulase-negative
Staphylococcus 7 (10%) 2 (15%) 0.57
Enterococcus 6 (9%) 0 0.27
Staphylococcus aureus 1 (1%) 0 0.67
Gram-negative cases 12 (17%) 2 (15%) 0.88
Moraxella 8 (11%) 0 0.2
Pseudomonas 2 (3%) 1 (8%) 0.39
Serratia 1 (1%) 1 (8%) 0.18
Das et al. reported favorable results of reduced intraocu-
lar inﬂammation at 1 and 4 weeks in eyes treated with IVD
[5]. Gan et al. additionally found a trend toward better visual
outcomes at 3 and 12 months in eyes treated with IVD [6].
Incontrast,Halletal.reportednodiﬀerenceininﬂammation
Table 2: Repeat culture results.






Number of eyes 11 (16%) 3 (23%) 0.52
Mean time, days (range) 20 (1–60) 14 (2–30) 0.64
Primary culture results
Streptococcus 4 (36%) 2 (67%)
Enterococcus faecalis 2 (18%) 0
Coagulase-neg Staph. 2 (18%) 1 (33%)
Enterobacter aerogenes 1( 9 % ) 0
No growth 2 (18%) 0 0.43
Repeat culture results
Streptococcus 0 1 (33%)
Enterococcus faecalis 2 (18%) 0
Coagulase-neg Staph. 00
Enterobacter aerogenes 00
No growth 9 (82%) 2 (67%) 0.57
Repeat culture positive rate 2 (3%) 1 (8%) 0.57
Table 3: VA outcomes.
IVD No IVD P value
71/84 (84%) 13/84 (16%)
VA, pre-
endophthalmitis n = 67 n = 13
Mean 20/90 20/70 0.57
Range 20/20-LP 20/25–20/400
VA, presentation n = 70 n = 13
Mean 0.9/200 1.7/200 0.23
Range 20/40-NLP 20/80-LP
VA, 1 month n = 66 n = 12
Mean 5/200 1.8/200 0.14
Range 20/25-NLP 20/25-NLP
≥3 lines
Improvement 44 (67%) 3 (25%) 0.01
logMARΔ 0.85 1.56 0.02
VA, 3 months n = 56 n = 9
Mean 7/200 3/200 0.36
Range 20/25-NLP 20/25-LP
≥3 lines
Improvement 36 (64%) 3 (33%) 0.14
logMARΔ 0.74 1.33 0.14
Table 4: Predictive factor ≥3 lines improvement.
IVD versus No IVD Odds ratio, (CI) P value
1 month 7.04 (1.63,30.43) 0.01
3 months 5.21 (1.07,25.37) 0.04
and VA outcomes at last followup in eyes treated with IVD
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Table 5: Comparative studies of IVD for bacterial endophthalmitis.
Clinical setting Culture results Inﬂammation VA outcomes Time
n Staph epi. Strep/Enterococcus Gram-negative
Das et al. [5] Postcataract and
trauma
IVD 29 n/a n/a n/a 2.6 score 86% success 3m o n t h s
No IVD 34 3.2 score1 71% success
Shah et al. [8] Postcataract
IVD 26 31% 12% 0 n/a 20/70 median 6m o n t h s
No IVD 31 35% 13% 3% 20/50 median2
Gan et al. [6] Postcataract
IVD 16 39% 8% 0 n/a 85% 20/200 or better 3m o n t h s
No IVD 13 50% 6% 0 50% 20/200 or better3
Hall et al. [7] Postcataract
IVD 26 46% 23% 0 0.3 cell/ﬂare 20/40 median last
followup No IVD 38 37% 5% 0 0.3 cell/ﬂare 20/50 median
Jacobs et al. Bleb-associated
IVD 70 10% 36% 17% n/a 7/200 mean 3m o n t h s
No IVD 13 15% 15% 15% 3/200 mean4
1Relative change in inﬂammation showed statistical signiﬁcance at 1 and 4 weeks, not at 3 months. 2P<0.05 , 3P = 0.055. 4Relative logMARΔ showed
statistical signiﬁcance at 1 month, not at 3 months.
Table 6: PPV versus T&I in present BAE series.
PPV T&I P value
29/83 (35%) 54/83 (65%)
VA, pre-
endophthalmitis n = 28 n = 53
Mean 20/55 20/50 0.3
Range 20/20-CF 20/20-LP
VA, presentation n = 30 n = 54
Mean LP HM 0.02
Range 20/80-LP 20/40-NLP
VA, 3 months n = 27 n = 39
Mean 3/200 20/390
Range 20/25-NLP 20/25-LP
logMARΔ 1.23 0.57 0.02
months in eyes treated with IVD [8]. The present series was
unique as it was the ﬁrst to study BAE cases that had a higher
rate of Streptococcus and Gram-negative cases.
BAE studies are limited by the relatively small number
of BAE cases. Conclusions in BAE studies are found in the
inherent limitations of retrospective nonrandomized data.
The majority of cases in the present study received IVD
which is similar to other BAE series [9–12]. Overall the
two groups compared in this study had similar baseline
demographic, clinical presentation, and initial culture data
(Table 1).
Ad i ﬀerence was found in the initial treatment of the two
groups. The majority of cases in both groups received T&I
as the initial treatment, however the percentage that received
initial PPV was higher in the IVD group. The eﬀect this
Table 7: PPVversusT&I:presentationVA ofLPor worseinpresent
BAE series.
PPV T&I P value
18/26 (69%) 8/26 (31%)
VA, pre-
endophthalmitis n = 18 n = 8
Mean 20/65 20/270 0.16
Range 20/20–1/200 20/25-HM
VA, presentation n = 18 n = 8
Mean LP LP 0.35
Range LP LP-NLP
VA, 3 months n = 17 n = 5
Mean 1/200 1/200
Range 20/60-NLP 20/200-LP
logMARΔ 1.71 1.18 0.46
diﬀerence had on the VA outcomes is unclear. A comparison
of PPV and T&I cases in this series showed that PPV cases
had signiﬁcantly worse mean VA at presentation and 3
months (Table 6).
When presentation of VA was LP or worse, 3-month-
logMARΔ was worse in the PPV group but not signiﬁcantly
(Table 7).
As VA outcomes with PPV were worse than T&I in this
series, it is unlikely that improved VA outcomes in the IVD
group were due to a higher percentage of initial treatment
with PPV.
Therepeatcultureresultsinthisseriesweresimilartothe
Endophthalmitis Vitrectomy Study (EVS). In the EVS, 14 of
420 (3.3%) had positive repeat cultures [14]. In the presentInternational Journal of Inﬂammation 5
series the overall repeat culture-positive rate was 3 of 83
(3.6%). Of note the EVS did not use IVD and the EVS had a
lowerrateofStreptococcusandGram-negative organisms,yet
the rate of persistent infection was similar in the EVS to the
present study. The present study conﬁrms the observation
made by Shaarawy et al. that persistent infection can occur
in bacterial endophthalmitis and appears to be more com-
mon with virulent organisms such as Streptococcus and En-
terococcus [15]. Although persistent infection occurred in the
present BAE series there was not a higher rate among the
cases treated with IVD.
VA outcomes in the present series conﬁrm the clinical
observationbyIrvineetal.thatintraocularsteroidsappeared
to hasten visual recovery [2]. At 1 month, 67% gained ≥3
lines in the IVD group compared to 25% in the group
that did not receive IVD. The VA gains in the IVD group
were more signiﬁcant at 1 month than 3 months. Logistic
regression did show that IVD was a predictive factor of ≥3
lines of improvement at both 1 and 3 months. VA gains may
have been due to a decrease in intraocular inﬂammation,
but a standardized manner of grading inﬂammation was not
employed in the present series.
Limitations of the current study include the retrospective
nature, small sample size in the control arm, and lack of a
deﬁnitive treatment protocol. This study does demonstrate
that IVD was associated with improved short-term VA out-
comes and did not potentiate infection in BAE.
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